MindMed Names Robert Barrow As CEO & Director, Announces Management Shake-Ups

Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Tuesday that Robert Barrow has been appointed CEO and member of the board of directors.

Barrow, an accomplished pharmaceutical executive and a recognized leader in the psychedelic industry, is bringing over a decade of experience leading organizations and drug development programs to the New York-based company.

Previously Barrow held the role of interim CEO and chief development officer of MindMed and the head of drug development and discovery at Usona Institute and CEO and director of Olatec Therapeutics.

Barrow holds an M.S. in Pharmacology from The State University and a B.S. from Wake Forest University, where he graduated summa cum laude. He honed his skills while working as a technical and strategic advisor to numerous large and small pharmaceutical companies.

"I am delighted to join MindMed's Board of Directors and look forward to building on the progress to date alongside our outstanding executive leadership …

Full story available on Benzinga.com

More MindMed Names Robert Barrow As CEO & Director, Announces Management Shake-Ups